Entwicklung eines chromatografischen Analyseverfahrens für die Echinocandine Micafungin und Anidulafungin in Humanplasma und Aspekte des Therapeutischen Drug Monitorings (TDM) der Echinocandine bei Patienten einer internistischen Intensivstation

Magdeburg, Univ., Med. Fak., Diss., 2014

Valeur de l'angio-TDM dans le bilan des hémoptysies

Objectifs: Évaluer l'apport de l'angioscanographie dans le cadre d'hémoptysies (1) dans la localisation des artères pathologiques, bronchiques (AB) et systémiques non bronchiques (ASNB) ou artérielles pulmonaires, (2) la localisation de la source du saignement et (3) les anomalies parenchymateuses responsables ou secondaires au saignement en comparaison avec les données angiographiques. Matériels et méthodes: 25 patients consécutifs (12 femmes, 13 hommes) d'un âge moyen de 50 ± 39 ans (min 15, max 89) ont été inclus dans l'étude. Les signes TDM ont été comparés aux signes angiographiques. Résultats: Les artères bronchiques ont été correctement identifiées dans 20 cas. Des ASNB anormales ont été identifiées dans 5 cas chez 4 patients. La TDM a correctement prédit le site d'embolisation dans 19 cas (76%). Les AB étaient responsables de l'hémoptysie dans 25 cas et les ASNB dans 4 cas. Les affections causales ou associées étaient les suivantes: carcinome bronchopulmonaire (n=11), hémangioendothéliome malin (n=1), mucoviscidose (n=7), hémoptysie cryptogénique au cours d'une BPCO (n=1), bronchectasies focales (n=4) et séquelles de tuberculose avec bronchectasies (n=1). Conclusion: Les signes directs et indirects en Angio-TDM sont utiles pour obtenir une visualisation globale des AB et ASNB anormales. Néanmoins, le site optimal d'embolisation ne peut toujours être prédit.

Adjonction d'un anesthésique local intra-articulaire lors d'arthro-TDM/IRM : utilité et avantages de la Bupivacaïne.

Objectifs: Une phase hyperalgique dans les 4 heures post-examen arthrographique est maintenant reconnue dans la littérature. Comment s'en amender ? Nous comparonsl'absence d'anesthésique à l'adjonction de deux différents anesthésiques locaux intra-articulaires(rapidocaïne/bupivacaïne) lors d'arthro-TDM/IRM. Matériels et méthodes: Après approbation du comité d'éthique, étude prospective chez 150 patients répartis aléatoirement en trois groupes : 1) sans anesthésique intra-articulaire, 2)rapidocaïne 1%, 3) bupivacaïne 0,25%. Recueil du score EVA (0-10) aux 5 temps suivants : avant injection (score de base), puis 20 minutes, 4 heures, 24 heureset 7 jours après la procédure. Résultats: Le pic douloureux maximal se trouve à 4h après la procédure (idem littérature). La douleur augmente en moyenne de 1,60 unités 4h après la procédure pour legroupe 1, de 1,22 unités pour le groupe 2 et de 0,29 unités pour le groupe 3. La différence entre les groupes 1 et 3 est statistiquement significative (p=0,002 -Tests ANOVA et de Sidak). Elle n'est pas significative entre les groupes 1 et 2 (p=0,536). La comparaison rapidocaïne et bupivacaïne est moins concluante(p=0,065). Conclusion: L'adjonction de bupivacaïne intra-articulaire devrait être réalisée lors d'examens arthrographiques, surtout afin d'améliorer le confort du patient mais aussi pourfavoriser son immobilité lors de l'acquisition des images TDM ou IRM .

Linee guida della consensus conference dell'ANGP per il monitoraggio plasmatico dei farmaci (TDM) in psichiatria. Aggiornamento 2011 =AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011

Therapeutic drug monitoring (TDM), i.e., the quantification of serum or plasma concentrations of medications for dose optimization, has proven a valuable tool for the patient-matched psychopharmacotherapy. Uncertain drug adherence, suboptimal tolerability, non-response at therapeutic doses, or pharmacokinetic drug-drug interactions are typical situations when measurement of medication concentrations is helpful. Patient populations that may predominantly benefit from TDM in psychiatry are children, pregnant women, elderly patients, individuals with intelligence disabilities, forensic patients, patients with known or suspected genetically determined pharmacokinetic abnormalities or individuals with pharmacokinetically relevant comorbidities. However, the potential benefits of TDM for optimization of pharmacotherapy can only be obtained if the method is adequately integrated into the clinical treatment process. To promote an appropriate use of TDM, the TDM expert group of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) issued guidelines for TDM in psychiatry in 2004. Since then, knowledge has advanced significantly, and new psychopharmacologic agents have been introduced that are also candidates for TDM. Therefore the TDM consensus guidelines were updated and extended to 128 neuropsychiatric drugs. 4 levels of recommendation for using TDM were defined ranging from "strongly recommended" to "potentially useful". Evidence-based "therapeutic reference ranges" and "dose related reference ranges" were elaborated after an extensive literature search and a structured internal review process. A "laboratory alert level" was introduced, i.e., a plasma level at or above which the laboratory should immediately inform the treating physician. Supportive information such as cytochrome P450 substrateand inhibitor properties of medications, normal ranges of ratios of concentrations of drug metabolite to parent drug and recommendations for the interpretative services are given. Recommendations when to combine TDM with pharmacogenetic tests are also provided. Following the guidelines will help to improve the outcomes of psychopharmacotherapy of many patients especially in case of pharmacokinetic problems. Thereby, one should never forget that TDM is an interdisciplinary task that sometimes requires the respectful discussion of apparently discrepant data so that, ultimately, the patient can profit from such a joint effort.

Intérêt de la tomographie par émission de positons couplée à la scanographie (TEP/TDM) dans les cancers urologiques [Value of positron emission tomography and computer tomography (PET/CT) for urologic malignancies].

Positron emission tomography is a functional imaging technique that allows the detection of the regional metabolic rate, and is often coupled with other morphological imaging technique such as computed tomography. The rationale for its use is based on the clearly demonstrated fact that functional changes in tumor processes happen before morphological changes. Its introduction to the clinical practice added a new dimension in conventional imaging techniques. This review presents the current and proposed indications of the use of positron emission/computed tomography for prostate, bladder and testes, and the potential role of this exam in radiotherapy planning.

Strategies for the development of tdm for targeted anticancer agents

Most of the novel targeted anticancer agents share classical characteristics that define drugs as candidates for blood concentration monitoring: long-term therapy; high interindividual but restricted intraindividual variability; significant drug-drug and drug- food interactions; correlations between concentration and efficacy/ toxicity with rather narrow therapeutic index; reversibility of effects; and absence of early markers of response. Surprisingly though, therapeutic concentration monitoring has received little attention for these drugs despite reiterated suggestions from clinical pharmacologists. Several issues explain the lack of clinical research and development in this field: global tradition of empiricism regarding treatment monitoring, lack of formal conceptual framework, ethical difficulties in the elaboration of controlled clinical trials, disregard from both drug manufacturers and public funders, limited encouragement from regulatory authorities, and practical hurdles making dosage adjustment based on concentration monitoring a difficult task for prescribers. However, new technologies are soon to help us overcome these obstacles, with the advent of miniaturized measurement devices able to quantify circulating drug concentrations at the point-of-care, to evaluate their plausibility given actual dosage and sampling time, to determine their appropriateness with reference to therapeutic targets, and to advise on suitable dosage adjustment. Such evolutions could bring conceptual changes into the clinical development of drugs such as anticancer agents, while increasing the therapeutic impact of population PK-PD studies and systematic reviews. Research efforts in that direction from the clinical pharmacology community will be essential for patients to receive the greatest benefits and the least harm from new anticancer treatments. The example of imatinib, the first commercialized tyrosine kinase inhibitor, will be outlined to illustrate a potential research agenda for the rational development of therapeutic concentration monitoring.

Therapeutic Drug Monitoring (TDM) of Imatinib: Effectiveness of Bayesian dose adjustment for CML patients enrolled in the Imatinib Concentration Monitoring (I-COME) study

Introduction: As imatinib pharmacokinetics are highly variable, plasma levels differ largely between patients under the same dosage. Retrospective studies in chronic myeloid leukemia (CML) patients showed significant correlations between low levels and suboptimal response, as well as between high levels and poor tolerability. Monitoring of trough plasma levels, targeting 1000 μg/L and above, is thus increasingly advised. Our study was launched to assess prospectively the clinical usefulness of systematic imatinib TDM in CML patients. This preliminary analysis addresses the appropriateness of the dosage adjustment approach applied in this study, which targets the recommended trough level and allows an interval of 4-24 h after last drug intake for blood sampling. Methods: Blood samples from the first 15 patients undergoing 1st TDM were obtained 1.5-25 h after last dose. Imatinib plasma levels were measured by LC-MS/MS and the concentrations were extrapolated to trough based on a Bayesian approach using a population pharmacokinetic model. Trough levels were predicted to differ significantly from the target in 12 patients (10 <750 μg/L; 2 >1500 μg/L along with poor tolerance) and individual dose adjustments were proposed. 8 patients underwent a 2nd TDM cycle. Trough levels of 1st and 2nd TDM were compared, the sample drawn 1.5 h after last dose (during distribution phase) was excluded from the analysis. Results: Individual dose adjustments were applied in 6 patients. Observed concentrations extrapolated to trough ranged from 360 to 1832 μg/L (median 725; mean 810, CV 52%) on 1st TDM and from 720 to 1187 μg/L (median 950; mean 940, CV 18%) on 2nd TDM cycle. Conclusions: These preliminary results suggest that TDM of imatinib using a Bayesian interpretation is able to target the recommended trough level of 1000 μg/L and to reduce the considerable differences in trough level exposure between patients (with CV decreasing from 52% to 18%). While this may simplify blood collection in daily practice, as samples do not have to be drawn exactly at trough, the largest possible interval to last drug intake yet remains preferable to avoid sampling during distribution phase leading to biased extrapolation. This encourages the evaluation of the clinical benefit of a routine TDM intervention in CML patients, which the randomized Swiss I-COME trial aims to.

Décès après interventions chirurgicales : investigation par l'angio-TDM post-mortem.

Objectifs: Des décès suite à une intervention chirurgicale sont autopsiés dans le but de déterminer le cause de la mort et investiguer une éventuelle erreur médicale . Le butde l'étude est d'évaluer l'utilité de l'angio-TDM post mortem pour ce type d'investigations médico-légales délicates. Matériels et méthodes: 145 cas médico-légaux ont été investigués. De ce collectif, huit cas impliquaient une intervention chirurgicale pour laquelle le décès pouvait être éventuellementimputé. Les résultats des examens radiologiques ont été comparés avec ceux obtenus par l'autopsie conventionnelle. Résultats: La cause du décès était soit un choc hémorragique ou septique, soit la combinaison d'une hémorragie et d'une aspiration de sang. Le diagnostic a pu être posélors de l'autopsie conventionnelle de même que lors de l'examen radiologique. Cependant, l'examen par angio-TDM a permis de détecter la source exacte deshémorragies dans cinq des six cas, alors que l'autopsie n'a permis de localiser le site hémorragique approximativement que dans trois cas . Conclusion: L'angio-TDM post-mortem est recommandée dans les cas de décès post-interventionnels. Elle permet de documenter les constatations et de réexaminer les casultérieurement. De plus, la source exacte des hémorragies peut être localisée ce qui est d'une grande importance dans ce genre de cas.